Pr Yohann Loriot
- Spécialité
- Oncologue médical, expert urologie
- Titre
- Chef adjoint du département des Essais Précoces (DITEP)
- Hôpital
- Gustave Roussy (Villejuif)
- Derniers articles
-
- Age Does not Affect the Efficacy of Antibody Drug Conjugates, But is Associated with High-Grade Adverse Events in Patients with Cancer Enrolled in Early Phase Clinical Trials. (16 mai 2025)
- Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Analyses of Patient-reported Outcomes and Quality-adjusted Time Without Symptoms or Toxicity from the JAVELIN Bladder 100 Trial. (2 mai 2025)
- Challenges in Defining Clinical Complete Response to Systemic Therapy in Muscle-invasive Bladder Cancer: Insights from the EORTC STARBURST Project. (15 avr. 2025)
- Prognostic Impact of Oncogenic Fibroblast Growth Factor Receptor Alterations in Patients With Advanced Solid Tumors in a Real-World Setting. (1 févr. 2025)
- Anti-ALK autoantibodies in patients with ALK-positive Non-Small Cell Lung Cancer (NSCLC): A monocentric experience. (30 juil. 2024)